← Leaderboards
Everett Stone
University Of Texas At Austin
$5,907,133
Attributed
$10,910,497
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,910,497 · 5
By mechanism
R01$10,910,497 · 5
Top collaborators
- George Georgiou Georgiou9 shared
- John Digiovanni5 shared
- Jonathan L. Coloff3 shared
- Lauren Ilyse Richie Ehrlich1 shared
Most similar at University Of Texas At Austin
Same institution · by research overlap
- George Georgiou Georgiou$8,894,674
- Yuri A Blednov$6,448,315
- Robert O. Messing$27,062,687
- John Digiovanni$26,040,423
- Lauren Ilyse Richie Ehrlich$12,985,621
Others in their field
Top investigators on “Engineering”
- David Heimbrook · Leidos Biomedical Research, Inc.$265,348,415
- Francis L Halzen · University Of Wisconsin-Madison$239,306,664
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
- Daniel Stanzione · Arizona State University$173,674,275
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$173,157,760
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
Research focus
EngineeringEnzymesIn VivoCancer TherapyTumor GrowthMalignant NeoplasmsTumorSerumHuman EngineeringMediatingMouse ModelExtracellularModalityPre-ClinicalTherapeutic EnzymeAmino AcidsPropertyStandard Of CareMetabolicPathway InteractionsCombined Modality TherapyCancer CellBiochemicalGrowth
Grant awards (18)
Depleting S1P to reverse immune exclusion for effective cancer immunotherapy$2,592,085
R01 · FY2025 · CA · contact PI
Therapeutic enzyme depletion of L-serine for cancer treatment$605,654
R01 · FY2025 · CA · contact PI
Therapeutic enzyme depletion of L-serine for cancer treatment$598,635
R01 · FY2024 · CA · contact PI
Therapeutic enzyme depletion of L-serine for cancer treatment$650,029
R01 · FY2023 · CA · contact PI
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors$370,782
R01 · FY2023 · CA · contact PI
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors$370,782
R01 · FY2022 · CA · contact PI
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors$378,348
R01 · FY2021 · CA · contact PI
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors$377,573
R01 · FY2020 · CA · contact PI
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors$373,697
R01 · FY2019 · CA · contact PI
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.$580,448
R01 · FY2018 · CA
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.$580,448
R01 · FY2017 · CA
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.$580,448
R01 · FY2016 · CA
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.$580,448
R01 · FY2015 · CA
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.$580,448
R01 · FY2014 · CA
Engineering and Evaluation of Human L-Methionase for Cancer Therapy$414,813
R01 · FY2014 · CA
Engineering and Evaluation of Human L-Methionase for Cancer Therapy$403,071
R01 · FY2013 · CA
Engineering and Evaluation of Human L-Methionase for Cancer Therapy$430,276
R01 · FY2012 · CA
Engineering and Evaluation of Human L-Methionase for Cancer Therapy$442,512
R01 · FY2011 · CA